Actualités santé à Aubagne | Conseils, prévention & infos

Séniors

Age- and sex-specific trends in dementia mortality among people with and without diabetes: a multi-country population-based analysis

Tuesday, May 19, 2026, 00:00

AIMS/HYPOTHESIS: Large-scale data on age- and sex-specific dementia mortality trends among people with diabetes remain limited, as most previous studies have been restricted to single countries or have not distinguished mortality by diabetes status. We estimated age- and sex-specific time trends in dementia mortality among individuals with and without diabetes from high-income jurisdictions. METHODS: We analysed aggregated mortality and demographic data using registries and administrative sources in Australia, Canada (Alberta and Ontario), France, Denmark, Finland and Scotland from 2000 to 2023. Poisson regression was used to estimate mortality rates for dementia as the underlying cause of death in people with and without diabetes at 60, 70, 80 and 90 years of age. RESULTS: A total of 114,559 and 589,706 dementia deaths were identified in over 42 and 244 million person-years of follow-up for individuals with and without diagnosed diabetes, respectively. Dementia mortality trends varied by age and jurisdiction but were generally consistent for both sexes. At younger ages (e.g. 60 and 70 years), the dementia mortality trends did not suggest any meaningful increases or decreases, except for in Scotland, which reported increasing dementia mortality over time only for those with diabetes. At older ages (e.g. 80 and 90 years), however, increases in dementia mortality were observed in most jurisdictions, ranging from 7.6% to 42.4% per 5 years. The magnitude of the increases was generally greater for those with diabetes. Mortality from dementia subtypes (e.g. Alzheimer's disease and vascular dementia) also increased over time in individuals aged 40-89 years, with greater increases in mortality rates for individuals with diabetes, specifically in Australia and Scotland. CONCLUSIONS/INTERPRETATION: Increases in dementia mortality were observed for those aged 80 years and above and were most marked for people with diabetes. These findings highlight the growing burden of dementia for health systems.

Impact of the first COVID-19 pandemic wave on hospitalizations and deaths caused by geriatric syndromes in France: a nationwide study

Thursday, January 1, 1970, 01:00

Impact de la première vague d’épidémie de COVID-19 sur les hospitalisations et la mortalité pour 10 syndromes gériatriques en France métropolitaine

Thursday, January 1, 1970, 01:00

Impact of the first COVID-19 pandemic wave on hospitalizations and deaths caused by geriatric syndromes in France: a nationwide study.

Promouvoir la participation sociale des personnes âgées : le dossier de la revue La Santé en action n°443, mars 2018

Thursday, January 1, 1970, 01:00

Santé publique France publie dans sa revue trimestrielle La Santé en action du mois d'avril 2018, un dossier consacré à la thématique " participation sociale des aînés " qui dresse un état des lieux de l'évolution des politiques publiques du bien vieillir, présente les particularités liées au grand âge et à l'accompagnement d'un proche.

« La confiance est déterminante pour les seniors isolés » [Interview]

Wednesday, March 25, 2026, 00:00

Le Pôle autonomie Pays d'Issoire Dômes et Montagne, dans le Puy-de-Dôme, a lancé un réseau d'ambassadeurs de la forme pour promouvoir le « bien-vieillir » sur son territoire. Des élus, des travailleurs sociaux et des bénévoles jouent un rôle de relais afin d'identifier les besoins des seniors, de faciliter leur accès à des actions de prévention en santé et de contribuer à lutter contre l'isolement et l'âgisme.

Vaccination

Effectiveness of nirsevimab immunisation on invasive pneumococcal disease in children nationwide in France: an observational cohort study

BACKGROUND: Invasive pneumococcal diseases (IPDs) remain a leading cause of morbidity and mortality in children worldwide, despite the widespread use of pneumococcal conjugate vaccines. Respiratory syncytial virus (RSV) disease is suspected to be associated with an increased risk of IPD. We assessed whether immunisation with nirsevimab, a monoclonal antibody targeting RSV, reduced the risk of IPD in children. METHODS: This population-based, retrospective cohort study used data from the French National Health Data System. All liveborn children in metropolitan France between Feb 6, 2023, and Jan 31, 2024, for whom nirsevimab immunisation status was available, were included. The date of nirsevimab immunisation defined the inclusion date of immunised children and their birth-month-matched non-immunised children. Children immunised with nirsevimab during the first year of life constituted the immunised group, whereas children non-immunised with nirsevimab constituted the non-immunised group. The primary outcome was hospitalisation for IPD within 6 months after inclusion. Propensity score analysis using inverse probability of treatment weighting (IPTW) was conducted to adjust for differences in baseline characteristics between the two groups. Immunisation effectiveness was calculated with the use of the following equation: effectiveness=100% × (1 - odds ratio [OR]), with the OR reflecting the association between nirsevimab and IPD. FINDINGS: Of the 608 641 children born in France during the study period, 527 971 were included, of whom 119 435 (22·6%) received nirsevimab. During the 6-month follow-up period, 112 cases of IPD occurred: 17 (14·2 per 100 000) in the immunised group versus 95 (23·3 per 100 000) in the non-immunised group. After IPTW, nirsevimab was associated with a 36% reduction in the odds of hospitalisation for IPD 6 months after immunisation (OR 0·64, 95% CI 0·46-0·82). 9 months after immunisation, effectiveness remained consistent with a 34% reduction (0·66, 0·51-0·85). INTERPRETATION: Nirsevimab immunisation in children younger than 12 months was associated with a lower risk of IPD for at least 6 months following immunisation. These findings suggest an additional benefit of nirsevimab implementation beyond RSV disease prevention, but further studies are needed to confirm these findings. FUNDING: AP-HP Research fellowship, ATIP-Avenir partnership, and AP-HP Foundation. TRANSLATIONS: For the French translation of the abstract see Supplementary Materials section.

Recommandations vaccinales contre les méningocoques : Fiche mémo

Cette fiche mémo est destinée à accompagner les professionnels de santé sur la vaccination contre les méningocoques. Elle présente dans un tableau récapitulatif les différents schémas de vaccination selon les sérogroupes de méningocoques et l’âge du patient.

Vaccination contre les infections à méningocoque : Repères pour votre pratique

Ce document destiné aux professionnels de santé permet de faire un point sur les principales caractéristiques actuelles de l’épidémiologie des infections invasives à méningocoque, les recommandations vaccinales et la vaccination en pratique.

Low seasonal influenza vaccine uptake and related 7C-attitudes among swine farm managers in Brittany, France, 2023-2024: a cross-sectional survey

BACKGROUND: Swine farmers are at increased risk of zoonotic influenza virus transmission. In France, seasonal influenza vaccination is recommended for swine farmers, yet little is known about vaccine uptake in this at-risk group. OBJECTIVES: To assess seasonal influenza vaccination uptake, its determinants, and associated attitudinal factors among swine farm managers in Brittany during the 2023-2024 influenza season. METHODS: A cross-sectional survey was conducted among a random sample of swine farm managers. Data were collected using a standardized questionnaire, including attitude items according to the French 7C-model of psychological antecedents of vaccination. RESULTS: Among 735 respondents, 14.0% [11.8%-16.4%] declared they have been vaccinated for the 2023-2024 season, and 35.0% [32.1%-38.0%] were unaware of the national recommendation. Only 33.5% demonstrated a knowledge score above 2/4. Vaccine uptake was significantly associated with older age, prior severe influenza (OR: 3.29 [1.97-5.50]), and receiving a vaccination voucher from the agricultural social security system (OR: 2.76 [1.66-4.59]). However, only 31.8% [28.6%-34.8%] reported having received one. Five among the seven components of the 7C-model were associated with vaccine uptake.Unvaccinated unwilling to vaccinate were characterised by low collective responsibility (R(2) = 16.98%) and unfavourable benefit-risk calculation (R(2) = 16.84%), while unvaccinated willing to vaccinate were mainly influenced by vaccine accessibility (R(2) = 17.32%) and negative social conformism (17.20%). CONCLUSION: Seasonal influenza vaccination uptake among swine farm managers is low. Targeting this population through tailored strategies is essential. These findings are relevant nationally and internationally and can inform One Health coordinated prevention efforts for professionals exposed to zoonotic influenza viruses.

Decreases in influenza vaccination coverage among nursing home healthcare workers and in measures to promote influenza vaccination, France, 2007/08 to 2024/25

BACKGROUND: Vaccination of residents and healthcare workers (HCWs) against influenza in nursing homes is an important prevention strategy. AIM: To describe trends in influenza vaccination coverage (VC) among HCWs working in nursing homes in France and measures implemented to support vaccination campaigns from 2007 to 2025, and to identify effectiveness of these measures. METHODS: We analysed data from seven nationwide cross-sectional studies conducted between seasons 2007/08 and 2024/25 and performed multivariate analysis using negative binomial regressions, to identify determinants. RESULTS: National influenza VC among HCWs decreased from 37.2% (95% CI: 35.7-39.4) in 2007/08 to 24.2% (95% CI: 23.2-25.1) in 2024/25 (mean: 39,740 HCWs per season, 6 seasons). Vaccination coverage disparities by category of HCWs (2024/25 VC of physicians: 56.3%; nurses: 34.2%; nursing assistants: 19.3%) were observed throughout the period. Measures to promote influenza vaccination were less frequently implemented over time: support of vaccination campaigns by the management team (from 2018/19: 89% to 2024/25: 52%), implementation of collective (68% to 49%) or individual information sessions (19% to 9%), distribution of information on influenza vaccines (64% to 53%) or influenza (83% to 69%). Seven measures exhibited effectiveness in 2018/19 compared to only four in 2024/25, which had less effectiveness. Management teams highlighted the strong reluctance of HCWs to receive influenza vaccination. CONCLUSIONS: Influenza VC among HCWs in nursing homes is marked by disparities among professional categories. To mitigate the decline in VC among HCWs, it is essential to implement effective measures to support the campaigns.

Vaccination des nourrissons, adolescents et jeunes adultes en Île-de-France. Bilan de la couverture vaccinale en 2025.

Points clés

Chez les nourrissons

L’obligation vaccinale contre les méningocoques ACWY mise en place depuis le 1er janvier 2025 chez les nourrissons suite à l’augmentation des cas d’infections invasives à méningocoques de types W et Y, a permis d’atteindre une couverture vaccinale élevée avec près de 88 % des nourrissons nés en 2025 ayant reçu la première dose de vaccin contre les méningocoques ACWY. Chez les enfants nés en 2024, avant le remplacement de la vaccination contre le méningocoque C par la vaccination ACWY, 83 % avaient reçu au moins une dose de vaccin méningococcique tétravalent ACWY à l’âge de 21 mois. Cette couverture vaccinale est inférieure à celle estimée en 2024 contre le méningocoque C. Rappelons qu’une vaccination commencée avec un vaccin monovalent C avant le 1er janvier 2025 chez les nourrissons doit être poursuivie avec un vaccin tétravalent ACWY.
En 2025, année de la mise en œuvre de l’obligation vaccinale contre les méningocoques B chez les nourrissons jusqu’à l’âge de 2 ans, la couverture vaccinale contres ces infections a nettement progressé avec 68,2 % des nourrissons nés en 2024 (âgés de 21 mois) à jour de leur vaccination (contre 58,6 % en 2024).
Les couvertures vaccinales pour les autres vaccinations obligatoires du nourrisson sont globalement élevées avec des niveaux supérieurs/proches à/de l’objectif cible de 95 % fixé par l’Organisation mondiale de la santé (OMS). Néanmoins, dans le contexte de la reprise de circulation du virus rougeoleux en France depuis 2024, il convient de rappeler que la couverture vaccinale des deux doses contre la rougeole, les oreillons et la rubéole doit dépasser cet objectif pour interrompre la circulation du virus qui peut conduire à des décès chez des personnes vulnérables. La vérification et la mise à jour de cette vaccination sont primordiales, chez les enfants et les adultes jeunes.

Chez les adolescents et jeunes adultes

Face à la gravité potentielle et la fréquence accrue des infections invasives à méningocoques à l’adolescence, la vaccination contre les méningocoques ACWY est recommandée chez les adolescents, avec un rattrapage chez les jeunes adultes. En 2025, seuls 17 % des 11-14 ans et 7,8 % des 15-24 ans avaient reçu une dose de ce vaccin. La vaccination contre les méningocoques ACWY doit s’intensifier dans cette tranche d’âge. L’intégration de cette vaccination dans les campagnes menées au collège à partir de 2026 permettra de renforcer la protection des jeunes face à ces infections. Les efforts pour améliorer la couverture vaccinale doivent se poursuivre afin d’atteindre une immunité de groupe et réduire la circulation des méningocoques dans les autres classes d’âge.
La couverture vaccinale contre les infections à papillomavirus (HPV) continue de progresser avec respectivement 40,8 % des filles et 26,5 % des garçons de 16 ans vaccinés avec un schéma complet. L’écart de couverture vaccinale entre les filles et les garçons continue de se réduire. Cette progression est encourageante, bien que la couverture vaccinale reste encore insuffisante pour réduire l’incidence des cancers liés à ces infections. L’objectif national fixé par la stratégie décennale de lutte contre les cancers est de 80 % chez les filles et les garçons d’ici 2030. Les efforts doivent aussi se poursuivre pour accélérer la progression de la vaccination contre les HPV afin d’atteindre cet objectif en s’appuyant sur les campagnes de vaccination au collège et en renforçant les messages sur l’importance de la vaccination des garçons.
Vacciner les garçons est aussi essentiel que vacciner les filles : cela participe à une protection équitable et durable.

Adhésion à la vaccination

Selon le Baromètre Santé publique France 2024, l’adhésion à la vaccination se maintient à un niveau élevé dans la région, notamment chez les jeunes avec 85 % des 18-25 ans se déclarant favorables à la vaccination en général.

Les vaccins à tous les âges : calendrier 2026 [Dépliant, Arabe]

Ce dépliant de 4 pages en Arabe présente de façon pédagogique et visuelle le calendrier 2026 des vaccins à faire tout au long de la vie.

Les vaccins à tous les âges : calendrier 2026 [Dépliant, Anglais]

Ce dépliant de 4 pages en anglais présente de façon pédagogique et visuelle le calendrier 2026 des vaccins à faire tout au long de la vie.

Déterminants de non-proposition de vaccination aux adolescents par les médecins généralistes français en 2025 : une étude qualitative

La couverture vaccinale des adolescents en France est insuffisante, qu’il s’agisse des rattrapages des vaccins de l’enfance ou des vaccinations recommandées dans cette tranche d’âge. Une étude qualitative, reposant sur des entretiens individuels semi-directifs, a été menée auprès d’un échantillon de 30 médecins généralistes de l’Hexagone ayant une patientèle d’adolescents, afin de comprendre les freins à la proposition vaccinale dans cette tranche d’âge et d’identifier des pistes d’amélioration. Les résultats suggèrent que la couverture vaccinale insuffisante des adolescents est rarement due à un manque d’adhésion à la vaccination dans cette tranche d’âge, de la part des médecins. Elle semble plutôt refléter des freins contextuels telle que la difficulté d’intégrer ce sujet dans les rares consultations des adolescents, le plus souvent occasionnées par d’autres motifs, les contraintes de temps lors de ces consultations, une certaine hésitation vaccinale des parents et le sentiment chez de nombreux médecins du caractère non urgent de ces vaccins. Cette dernière perception est renforcée par les larges tranches d’âge des recommandations vaccinales chez les adolescents. Enfin le caractère changeant du calendrier vaccinal apparaît parfois comme un frein, en particulier pour l’appropriation de nouvelles vaccinations. À cet égard, l’élaboration de supports plus adaptés aux contraintes de la pratique de la médecine générale permettrait d’aborder plus facilement ce sujet lors des consultations. Une réflexion sur le passage d’une logique de tranches d’âge à celle d’âges fixes pour les recommandations vaccinales pourrait être initiée. Enfin la promotion des consultations de suivi médical de l’adolescent permettrait de disposer d’un moment favorable à la proposition vaccinale par les médecins généralistes.

Tabac

Lifetime sexual violence and tobacco, alcohol, and cannabis use among French adults: A national survey

OBJECTIVE: Sexual violence can lead to significant health impacts, including higher risk of substance use. This study examines the association between lifetime experiences of sexual violence and substance use in a large nation-wide sample of French adults. METHODS: Data were drawn from the 2017 Health Barometer, a cross-sectional survey of 25,319 French adults aged 18-75, conducted in Mainland France between January and July 2017. Five substance use outcomes were examined: daily tobacco use, heavy drinking, regular binge drinking, monthly cannabis use, and problematic cannabis use. Multivariable logistic regression models were used to assess the association between sexual violence and each of these outcomes. RESULTS: A total of 9.5% of women and 2% of men reported having experienced sexual violence. In adjusted analyses, lifetime experience of sexual violence was associated with increased odds of all five substance use outcomes. Lifetime sexual violence was also linked to study outcomes in stratified analyses by sex, with particularly strong associations for monthly cannabis use (women aOR = 2.53, 1.90-3.34; men aOR = 2.10, 1.37-3.16). CONCLUSIONS: These findings support the need for integrated care addressing both sexual violence history and substance use among sexual violence victims-survivors.

Smoking and social inequalities in France, 20 years of evolution: A secondary dataset analysis of health barometers

INTRODUCTION: Since the early 2000s, smoking prevalence has declined overall in France. This study aims to describe the evolution of social inequalities in smoking in relation to anti-smoking policy between 2000 and 2021. METHODS: This study is a secondary analysis of data from Santé Publique France's Health Barometers, cross-sectional telephone surveys conducted between 2000 and 2021 on random samples of the French population aged 18-75 years (between 9074 and 28224 people were surveyed, depending on the edition). Evolutions in prevalence according to socio-economic status (level of education, income, and occupational status) were modeled using Poisson regression. RESULTS: Overall, social inequalities related to smoking increased between 2000 and 2021, with the prevalence of daily smoking rising among individuals with lower levels of education (from 30% to 32%), lower incomes or unemployed, while declining among more advantaged groups (e.g. from 28% to 17% for individuals with the highest levels of education). The analysis reveals three distinct phases: an increase in inequalities between 2000 and 2016, e.g. the association between smoking and a level of education below high school increased (adjusted interaction term, AIT=1.027; 95% CI: 1.021-1.033, per year) compared to those with a level of education above high school. Disparities then stabilized between 2016 and 2019. Finally, a resumption of the increase in inequalities related to education and income was observed between 2019 and 2021, e.g. over time, the association between smoking and a level of education below high school increased (AIT=1.071; 95% CI: 1.001-1.141). CONCLUSIONS: The 2016-2019 period was marked by the first national tobacco control plan, including numerous measures that addressed social inequalities. Over the same period, smoking declined among all socio-economic groups, and differences in smoking prevalence according to socio-economic status have stabilized, bringing an end to 16 years of increase. Unfortunately, inequality began to rise again in 2020-2021, during the COVID-19 pandemic.

Prévalence du tabagisme et du vapotage en France hexagonale en 2022 parmi les 18-75 ans

Introduction – Après une baisse d’une ampleur inédite en France de la prévalence tabagique entre 2014 et 2019, celle-ci s’est stabilisée depuis. Dans un contexte post crise liée à la Covid-19, l’objectif principal de cette étude est d’estimer la prévalence du tabagisme en 2022 et de décrire son évolution récente. Méthodes – Les données utilisées proviennent d’une enquête téléphonique sur un échantillon aléatoire, menée entre mars et juillet 2022, comprenant au total 3 229 individus de 18-75 ans résidant en France métropolitaine. Résultats – En 2022, en France métropolitaine, plus de trois personnes de 18-75 ans sur dix déclaraient fumer (31,8 %) et un quart déclaraient fumer quotidiennement (24,5 %). Ces prévalences sont stables par rapport à 2020 et 2019. La prévalence du tabagisme quotidien reste supérieure parmi les hommes (27,4 % versus 21,7 % parmi les femmes). Un écart de 14 points est observé entre les personnes n’ayant aucun diplôme ou un diplôme inférieur au Baccalauréat (30,8 %) et les titulaires d’un diplôme supérieur au Baccalauréat (16,8 %). Conclusion – La stabilité de la prévalence tabagique observée depuis la crise liée à la Covid-19 se poursuit en 2022. Les inégalités sociales en matière de tabagisme restent très marquées et leur réduction sera un enjeu majeur pour le futur 3e plan de lutte contre le tabac.

Comment arrêter de fumer

Dépliant d'information qui fait le point sur les questions du sevrage tabagique : Vers qui s'orienter pour arrêter de fumer ? Quelles sont les solutions ? Qu'est-ce qu'une thérapie comportementale et cognitive ? Les substituts nicotiniques sont-ils efficaces ? Que dire du bupropion LP et de la varénicline ? Quid de la cigarette électronique ? Fait-on des économies en arrêtant de fumer? Que rembourse l'assurance maladie, etc. Il détaille également les services de Tabac info service.

Tabac

Malgré une légère diminution par rapport à 2015, le tabac reste responsable de plus de 68 000 décès prématurés en 2023, soit 11 % de la mortalité totale, ce qui en fait toujours la première cause de mortalité évitable en France. Cependant, depuis le lancement du premier Plan national de réduction du tabagisme (PNRT), le nombre de fumeurs quotidiens de 18 à 75 ans a diminué de 4 millions en 10 ans.

6ème édition du défi Mois sans tabac : les inscriptions sont ouvertes !

Cette semaine signe le lancement de la 6^ème édition de #MoisSansTabac à l’initiative de Santé publique France et du Ministère des Solidarités et de la Santé, en partenariat avec l’Assurance Maladie.

7ème édition de Mois sans tabac : Inscrivez-vous dès maintenant pour relever le défi !

Le 1er novembre 2022, Mois sans tabac revient pour sa 7ème édition. Cette opération, mise en place depuis 2016 par Santé publique France et le Ministère de la Santé et de la Prévention, en partenariat avec l’Assurance Maladie, suscite une forte adhésion avec plus d’1 million d’inscriptions comptabilisées depuis son lancement.

A l’occasion de la Journée Mondiale Sans Tabac du 31 mai 2021, le ministère des Solidarités et de la Santé salue l’ensemble des actions engagées pour renforcer la lutte contre le tabagisme

Dans le contexte de levée progressive des restrictions et de réouverture des lieux publics, le ministère des Solidarités et de la Santé rappelle qu’il est plus que jamais nécessaire de favoriser la convivialité dans des espaces publics et environnements sans tabac, favorables à un cadre de vie plus sain. Santé publique France lance une nouvelle campagne qui vise à accélérer le mouvement de dénormalisation du tabac en cherchant à rendre désirable une vie sans tabac et incite le grand public à rejoindre ainsi les 50 millions de Français qui ne fument pas.

9e édition du Mois sans tabac : inscriptions ouvertes pour relever le défi d’une vie sans tabac !

Les inscriptions au Mois sans tabac, le défi collectif qui invite les fumeurs à arrêter de fumer pendant 30 jours consécutifs, sont ouvertes. Cet événement national, mis en place par le Ministère de la Santé et de l’Accès aux soins et Santé publique France, en partenariat avec l’Assurance Maladie, est devenu incontournable depuis sa création en 2016.

"Les tentatives" : la nouvelle campagne gouvernementale pour encourager à l’arrêt du tabac avec un partenariat inédit avec l’émission « Koh-Lanta »

Malgré une baisse de la prévalence du tabagisme en France depuis 2021, le tabac reste la première cause de mortalité évitable dans notre pays. Aujourd’hui, Santé publique France et le Ministère du travail, de la santé, des solidarités et des familles, en collaboration avec l'Assurance Maladie, lancent une nouvelle campagne à destination des fumeurs.

Diabète

Can we optimize selective screening of gestational diabetes mellitus? A multivariable predictive model on population-based data from the French National Perinatal Surveys

OBJECTIVE: Selective screening for gestational diabetes mellitus (GDM) remains a widespread strategy. Variation in criteria identifying at-risk women questions its accuracy, with implications for clinical outcome and resource allocation. Our aim was to develop and externally validate a multivariable prediction model with improved performance compared to the current French pre-screening selection strategy. METHODS: Data was derived from the population-based 2021 (derivation sample) and 2016 (external validation sample) French National Perinatal Survey (ENP). Independent predictors of GDM were identified using a multivariable logistic regression model. Predictive performance was assessed through the area under the receiver operating characteristic curve. Diagnostic performance was assessed through sensitivity, specificity, and accuracy. Sensitivity analyses were conducted: (1) in maternity centers with quasi-universal screening, (2) outcome strictly defined as GDM cases associated with large-for-gestational-age births and (3) implementing doubly robust estimators of sensitivity and specificity. RESULTS: The study population included 10834 women in the derivation sample and 11633 in the validation sample, where the prevalence of GDM was respectively 19.4% and 13.2%. Maternal age, body mass index, obstetric history, family history of diabetes, and maternal country of birth were independent predictors of GDM. The prediction model demonstrated a statistically significant improvement in specificity (0.49 [95% CI: 0.48-0.50] vs. 0.46 [95% CI: 0.45-0.47]) and overall diagnostic accuracy (0.53 [95% CI: 0.52-0.54] vs. 0.50 [95% CI: 0.49-0.51]). CONCLUSION: The prediction model modestly improved performance while maintaining the same screening rate, though it is unlikely to justify additional complexity of implementation, therefore limiting its added-value in clinical practice. These findings suggest that available clinical predictors already capture most of the predictive information relevant for selective screening.

Enriching administrative data to extend real-world knowledge of diabetes: design of the French national diabetes survey Entred 3

Aims: The significant burden of diabetes requires reliable information collection. While administrative databases are an essential source of information, they have limitations, especially when they are relied upon as the sole data source. This article presents how enriching administrative databases with survey-based data can overcome these limitations and improve knowledge of diabetes. Methods: Based on a random sample of 12,772 people living with diabetes in France, the Entred 3 study complements administrative data with self-reported and medical data, including biological test results. Results: By complementing administrative data with a multi-source approach, we conducted a study on a wider range of diabetes-related topics (e.g., quality of life, health literacy, glycemic control, and individual socio-economic information) for a sample representative of the population treated pharmacologically for diabetes in France, with the data further analyzed by diabetes type. In European France, administrative data were extracted for 8,138 individuals (93.2%) and 3,166 individuals (36.3%) participated in the patient questionnaire. Of these, 1,332 of their physicians also completed a questionnaire (42.1%). Among people living with diabetes, 94.1% had type 2 diabetes, and 5.1% had type 1 diabetes. Conclusion: The real-world data collected in the Entred 3 study provide essential epidemiological, medical, economic, and social information for the development and direction of prevention campaigns aimed at improving medical practices, health status, and quality of life for people living with diabetes. © 2026 The Authors

Closing the implementation gap: the Joint Action on Cardiovascular Diseases and Diabetes (JACARDI) as a proof of-concept for Europe's Safe Hearts Plan

Commentary. No abstract available.

Les pilotes JACARDI déployés en France

Tout savoir sur les projets pilotés par Santé publique France et déployés en France dans le cadre du projet JACARDI

Food Coloring Additives and Incidence of Type 2 Diabetes in the NutriNet-Santé Prospective Cohort

OBJECTIVE: To investigate potential association between exposure to food coloring additives and type 2 diabetes incidence. RESEARCH DESIGN AND METHODS: The study followed 108,723 participants (79.2% female, mean age 42.5 [SD 14.6] years) from the French NutriNet-Santé cohort (2009-2023). Dietary data were assessed using repeated 24-h dietary records, including industrial food brands. Cumulative time-dependent exposure to food additives was evaluated through multiple composition databases and ad hoc laboratory assays in food matrices. Associations between exposures to food coloring additives (sex-specific tertiles if proportion of exposed participants was more than two-thirds, or nonexposed/lower/higher exposed based on sex-specific median otherwise) and type 2 diabetes incidence were assessed using multivariable Cox proportional hazards models. RESULTS: There were 1,131 incident type 2 diabetes cases diagnosed (median follow-up, 8.05 years). After false discovery rate correction, intakes of the following colors were associated with higher type 2 diabetes incidence: total food coloring additives (hazard ratio [HR]higher vs. non/lower consumers 1.38 [95% CI 1.17-1.63], P = 0.0002), total caramel (1.43 [1.21-1.67], P = 0.0002), plain caramel (1.46 [1.26-1.70], P = 0.0002), sulfite ammonia caramel (1.30 [1.07-1.59], P = 0.007), total carotene (1.27 [1.08-1.48], P = 0.007), carotenoids (1.39 [1.19-1.62], P = 0.0002), β-carotene (1.44 [1.23-1.68], P = 0.0002), paprika-capsanthin-capsorubin (1.26 [1.08-1.46], P = 0.004), lutein (1.20 [1.02-1.40], P = 0.0002), curcumin (1.49 [1.29-1.73], P = 0.0002), cochineal-carminic acid-carmines (1.27 [1.10-1.48], P = 0.003), and anthocyanins (1.40 [1.17-1.68], P = 0.0002). CONCLUSIONS: Several positive associations were observed between exposure to natural and synthetic food coloring additives and type 2 diabetes incidence. Further studies are needed to gain insights into underlying mechanisms, and if confirmed, call for reevaluation of food coloring additives to protect consumer health.

Health literacy profiles of people living with type 2 diabetes: a cluster-based approach to inform tailored interventions-the Entred 3 study

INTRODUCTION: Health literacy is a multidimensional determinant of health that influences diabetes outcomes and social inequities in health (SIH). Studies often measure it unidimensionally, failing to capture people's diverse health literacy skills. We identified multidimensional health literacy profiles among adults living with type 2 diabetes (T2D) in France and described their clinical, behavioral and social characteristics with a view to informing future tailored interventions. RESEARCH DESIGN AND METHODS: This study used a cross-sectional design based on a subsample of the Entred 3 national survey, combining self-reported questionnaire data with linked administrative health data covering the previous 10 years. Health literacy was assessed using the Health Literacy Questionnaire (HLQ) among 510 individuals with T2D who completed the cross-sectional survey online. Hierarchical clustering based on standardized HLQ scores identified distinct health literacy clusters. RESULTS: We identified 13 health literacy clusters among the online survey participants, labelled from A to M, five requiring tailored public health and clinical responses. Substantial heterogeneity concerning health literacy skills and associations with SIH and health outcomes was observed. For example, cluster A demonstrated strong self-management skills counteracted by severe barriers to care navigation and information comprehension in a highly vulnerable setting. Furthermore, cluster D reflected globally low health literacy scores, poor health outcomes and high exposure to risk factors despite recent diabetes diagnosis. A third example is cluster K, which highlighted strong relational and cognitive skills but limited engagement in self-care and significant exposure to risk factors despite favorable socioeconomic conditions. CONCLUSIONS: Health literacy profiles reflect complex combinations of skills, risks and social determinants, which can potentially inform how to tailor public health interventions, so that no group is left behind.

Contextual impact of socio-economic inequalities on health: a case study of COVID-19 mortality among populations with and without diabetes in France

AIMS: The aim was to describe the impact of socio-economic inequalities (SEI) on COVID-19 mortality in people aged 45 years and over living with or without diabetes during the two epidemic waves of 2020 (wave 1 (W1): March-May; wave 2 (W2): September-December) in European France. METHODS: People living with pharmacologically treated diabetes were identified using a validated algorithm from the French National Health Data System. COVID-19 mortality in 2020 was obtained from the French Medical Causes of Death database. SEI were measured using the French Deprivation Index at municipality level (FDep; with Q1 corresponding to people living in the least deprived). Age-standardised COVID-19 mortality was calculated by FDep quintiles for each month of the year and by sex. The relative risk of COVID-19 mortality associated with FDep quintiles (with Q1 as the reference) according to diabetes status and epidemic wave was estimated by sex using an adjusted log-linear Poisson model. RESULTS: During W1, when only collective measures were available (lockdown), no social gradient was observed, and it was even the least deprived women with diabetes (Q1) who had a higher risk of COVID-19 mortality. Among men with diabetes, only the most deprived (Q5) had a slightly higher risk of COVID-19 mortality than the least deprived (Q1). The same results were overall found in people without diabetes.During W2, after the implementation of the first individual preventive measures (mask), COVID-19-related mortality followed a positive SEI gradient among men and women with and without diabetes, with higher rates in the most deprived groups (Q5). Moreover, the influence of SEI was greater in women without diabetes in the most deprived groups (Q3, Q4, Q5) than in women with diabetes. CONCLUSION: Our study highlights the importance of integrating the principles of equity, which give consideration to the most vulnerable, into the development of individual prevention measures.